Abstract
Mortalin is a member of Hsp70 family of stress chaperones. It was first identified as a protein involved in the senescence of mouse cells. Genetic studies revealed that there are two mouse mortalin alleles coding for two proteins (mot-1 and mot-2) that differ in only two amino acids in the carboxy-terminus, but have contrasting activities. Whereas mot-1 accelerated senescence, mot-2 extended the lifespan of mouse cells in culture. In human cells, only one kind of mortalin protein has been identified so far and is shown to be functionally equivalent to mouse mot-2. Whereas mortalin is enriched in cancer cells and contributes to carcinogenesis, the old age brain disorders show its deficiency. As we demystify its deux de machina, accumulating evidence reveal that mortalin may be “druggable” bidirectionally to either treat cancer or neuro-degenerative disorders.
Keywords: Mortalin, chaperone, cancer, aging, target, therapy, Hsp70, alleles, senescence, neuro-degenerative disorders.
Current Pharmaceutical Design
Title:Druggability of Mortalin for Cancer and Neuro-Degenerative Disorders
Volume: 19 Issue: 3
Author(s): Custer C. Deocaris, Wen-Jing Lu, Sunil C. Kaul and Renu Wadhwa
Affiliation:
Keywords: Mortalin, chaperone, cancer, aging, target, therapy, Hsp70, alleles, senescence, neuro-degenerative disorders.
Abstract: Mortalin is a member of Hsp70 family of stress chaperones. It was first identified as a protein involved in the senescence of mouse cells. Genetic studies revealed that there are two mouse mortalin alleles coding for two proteins (mot-1 and mot-2) that differ in only two amino acids in the carboxy-terminus, but have contrasting activities. Whereas mot-1 accelerated senescence, mot-2 extended the lifespan of mouse cells in culture. In human cells, only one kind of mortalin protein has been identified so far and is shown to be functionally equivalent to mouse mot-2. Whereas mortalin is enriched in cancer cells and contributes to carcinogenesis, the old age brain disorders show its deficiency. As we demystify its deux de machina, accumulating evidence reveal that mortalin may be “druggable” bidirectionally to either treat cancer or neuro-degenerative disorders.
Export Options
About this article
Cite this article as:
C. Deocaris Custer, Lu Wen-Jing, C. Kaul Sunil and Wadhwa Renu, Druggability of Mortalin for Cancer and Neuro-Degenerative Disorders, Current Pharmaceutical Design 2013; 19 (3) . https://dx.doi.org/10.2174/1381612811306030418
DOI https://dx.doi.org/10.2174/1381612811306030418 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
STAT3 as a Central Regulator of Tumor Metastases
Current Molecular Medicine Process Variables and Design of Experiments in Liposome and Nanoliposome Research
Mini-Reviews in Medicinal Chemistry Efficacy and Cardiovascular Safety of Thiazolidinediones
Current Drug Safety Future Directions in the Treatment of Neuropathic Pain: A Review on Various Therapeutic Targets
CNS & Neurological Disorders - Drug Targets Recent Patents on Biomarkers in Oral Cancers
Recent Patents on Biomarkers Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Flavonoid Derivatives Targeting BCR-ABL Kinase: Semisynthesis, Molecular Dynamic Simulations and Enzymatic Inhibition
Current Topics in Medicinal Chemistry Progress in Imaging Agents of Cell Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Inhibitors of Nitrogen Oxide Species Production in Animal Models of Inflammation and Future Directions for Therapy in Inflammatory Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases
Current Protein & Peptide Science Advances in Drug Discovery to Assess Cholinergic Neurotransmission: A Systematic Review
Current Drug Discovery Technologies Extracellular ATP and Neurodegeneration
Current Drug Targets - CNS & Neurological Disorders Trends of SAPHO Therapy: Should we be Content?
Current Rheumatology Reviews Computer-Aided Drug Design for Cancer-Causing H-Ras p21 Mutant Protein
Letters in Drug Design & Discovery Genetic Variations in Telomere Maintenance, with Implications on Tissue Renewal Capacity and Chronic Disease Pathologies
Current Pharmacogenomics and Personalized Medicine Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Cellular Functions of Vaults and their Involvement in Multidrug Resistance
Current Drug Targets Four-Component Synthesis of 1,2-Dihydropyridine Derivatives and their Evaluation as Anticancer Agents
Medicinal Chemistry Chinese Medicinal Herbs as Source of Antioxidant Compounds – Where Tradition Meets the Future
Current Medicinal Chemistry Biologics for ANCA-Associated Vasculitis
Inflammation & Allergy - Drug Targets (Discontinued)